Caroxazone

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Caroxazone
DrugBank Accession Number
DB09254
Background

Caroxazone is an antidepressant that has been withdrawn from the market. It is a reversible monoamine oxidase inhibitor (MAOI) of both A and B monoamine oxidase subtypes. However, it presents a five-fold preference for the MAO-B subtype.

Type
Small Molecule
Groups
Withdrawn
Structure
Weight
Average: 206.201
Monoisotopic: 206.06914219
Chemical Formula
C10H10N2O3
Synonyms
  • Caroxazone
External IDs
  • F.I. 6654

Pharmacology

Indication

For the treatment of depression.

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
1,2-BenzodiazepineThe risk or severity of CNS depression can be increased when Caroxazone is combined with 1,2-Benzodiazepine.
AbaloparatideCaroxazone may increase the orthostatic hypotensive activities of Abaloparatide.
AbciximabThe risk or severity of bleeding and hemorrhage can be increased when Caroxazone is combined with Abciximab.
AcarboseCaroxazone may increase the hypoglycemic activities of Acarbose.
AcebutololCaroxazone may increase the hypotensive activities of Acebutolol.
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
International/Other Brands
Surodil / Timostenil

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as benzoxazines. These are organic compounds containing a benzene fused to an oxazine ring (a six-membered aliphatic ring with four carbon atoms, one oxygen atom, and one nitrogen atom).
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Benzoxazines
Sub Class
Not Available
Direct Parent
Benzoxazines
Alternative Parents
Alpha amino acids and derivatives / Benzenoids / Carbamate esters / Primary carboxylic acid amides / Organic carbonic acids and derivatives / Oxacyclic compounds / Azacyclic compounds / Organopnictogen compounds / Organonitrogen compounds / Organic oxides
show 2 more
Substituents
Alpha-amino acid or derivatives / Aromatic heteropolycyclic compound / Azacycle / Benzenoid / Benzoxazine / Carbamic acid ester / Carbonic acid derivative / Carbonyl group / Carboxamide group / Carboxylic acid derivative
show 9 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available
Affected organisms
  • Humans and other mammals

Chemical Identifiers

UNII
807N226MNL
CAS number
18464-39-6
InChI Key
KYCBWEZLKCTALM-UHFFFAOYSA-N
InChI
InChI=1S/C10H10N2O3/c11-9(13)6-12-5-7-3-1-2-4-8(7)15-10(12)14/h1-4H,5-6H2,(H2,11,13)
IUPAC Name
2-(2-oxo-3,4-dihydro-2H-1,3-benzoxazin-3-yl)acetamide
SMILES
NC(=O)CN1CC2=CC=CC=C2OC1=O

References

General References
  1. Cecchini S, Petri P, Ardito R, Bareggi SR, Torriti A: A comparative double-blind trial of the new antidepressant caroxazone and amitriptyline. J Int Med Res. 1978;6(5):388-94. [Article]
  2. Moretti A, Caccia C, Martini A, Bonollo L, Amico A, Sega R, Nicolella V, Nicolis FB: Effect of caroxazone, a new antidepressant drug, on monoamine oxidases in healthy volunteers. Br J Clin Pharmacol. 1981 May;11(5):511-5. [Article]
PubChem Compound
29083
PubChem Substance
310265157
ChemSpider
27057
ChEBI
134867
ChEMBL
CHEMBL2104164
ZINC
ZINC000000001095
Wikipedia
Caroxazone

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility11.9 mg/mLALOGPS
logP-0.25ALOGPS
logP0.12Chemaxon
logS-1.2ALOGPS
pKa (Strongest Acidic)15.42Chemaxon
pKa (Strongest Basic)-4.7Chemaxon
Physiological Charge0Chemaxon
Hydrogen Acceptor Count2Chemaxon
Hydrogen Donor Count1Chemaxon
Polar Surface Area72.63 Å2Chemaxon
Rotatable Bond Count2Chemaxon
Refractivity52.12 m3·mol-1Chemaxon
Polarizability19.9 Å3Chemaxon
Number of Rings2Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterYesChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSsplash10-052f-6900000000-16cb76527733eb4a1b23
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-0a4i-0290000000-c01837f08147b40c8eb5
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-052b-9430000000-27395885edce353af22e
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-0006-9200000000-d9213fc15c43f55bb087
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-0a4l-2940000000-c362d5cbf3a4f3bb1ca1
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-01ox-9500000000-e9391f4bfe6af1c671d3
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-0006-9000000000-98e63bab0d0626821d60
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-151.5487529
predicted
DarkChem Lite v0.1.0
[M-H]-132.5294
predicted
DeepCCS 1.0 (2019)
[M+H]+152.3247529
predicted
DarkChem Lite v0.1.0
[M+H]+135.88344
predicted
DeepCCS 1.0 (2019)
[M+Na]+151.7770529
predicted
DarkChem Lite v0.1.0
[M+Na]+145.29782
predicted
DeepCCS 1.0 (2019)

Drug created at October 24, 2015 04:21 / Updated at February 21, 2021 18:52